{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:20:34Z","timestamp":1783351234767,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eprac.2022.08.006","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T22:03:30Z","timestamp":1660341810000},"page":"1210-1215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Factors Associated With Radioactive Iodine Therapy\u2013Acquired Nasolacrimal Duct Obstruction"],"prefix":"10.1016","volume":"28","author":[{"given":"Irene T.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Jessop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eprac.2022.08.006_bib1","first-page":"120","article-title":"Iodine-131 for therapy of thyroid diseases. Physical and biological basis","volume":"15","author":"Wyszomirska","year":"2012","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.006_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3803\/EnM.2014.29.3.233","article-title":"Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology","volume":"29","author":"Chung","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.006_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.nic.2008.03.008","article-title":"Radioiodine imaging and treatment in thyroid disorders","volume":"18","author":"Griggs","year":"2008","journal-title":"Neuroimaging Clin N Am"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.006_bib4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/thy.2010.0055","article-title":"Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review","volume":"20","author":"Sawka","year":"2010","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.006_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3121\/cmr.2007.763","article-title":"Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited","volume":"5","author":"Doi","year":"2007","journal-title":"Clin Med Res"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.006_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1089\/thy.2009.1611","article-title":"The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer","volume":"19","author":"Van Nostrand","year":"2009","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.006_bib7","first-page":"738","article-title":"Salivary and lacrimal gland dysfunction (Sicca syndrome) after radioiodine therapy","volume":"42","author":"Solans","year":"2001","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.006_bib8","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1210\/jc.2002-020210","article-title":"Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma","volume":"87","author":"Kloos","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.006_bib9","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1089\/thy.2015.0657","article-title":"Lacrimal system obstruction after radioiodine therapy in differentiated thyroid carcinomas: a prospective comparative study","volume":"26","author":"da Fonseca","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.006_bib10","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/IOP.0000000000000066","article-title":"Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy","volume":"31","author":"Savage","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.006_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.2011.0186","article-title":"Epiphora after radioactive iodine ablation for thyroid cancer","volume":"23","author":"Sun","year":"2013","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.006_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.IOP.0000092802.75899.F8","article-title":"Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma","volume":"19","author":"Shepler","year":"2003","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.006_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.IOP.0000117340.41849.81","article-title":"Nasolacrimal obstruction secondary to I(131) therapy","volume":"20","author":"Burns","year":"2004","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.eprac.2022.08.006_bib14","first-page":"2479","article-title":"Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases","volume":"8","author":"Al-Qahtani","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.006_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/IOP.0000000000000647","article-title":"Iodine-131 therapy and nasolacrimal duct obstructions: what we know and what we need to know","volume":"32","author":"Ali","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.006_bib16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/MNM.0b013e3283570fb8","article-title":"Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer","volume":"33","author":"Fard-Esfahani","year":"2012","journal-title":"Nucl Med Commun"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.006_bib17","first-page":"97","article-title":"[Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma]","volume":"75","author":"da Fonseca","year":"2012","journal-title":"Arq Bras Oftalmol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.006_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.iop.0000179369.75569.a8","article-title":"Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients","volume":"21","author":"Morgenstern","year":"2005","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.006_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IOP.0000000000000603","article-title":"Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT","volume":"33","author":"Ali","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.006_bib20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1080\/02713683.2021.1878229","article-title":"Clinical and demographic characteristics of tearing in patients after radioiodine ablation for differentiated thyroid cancer","volume":"46","author":"Yartsev","year":"2021","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.006_bib21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1530\/eje.0.1410382","article-title":"Immunohistochemical analysis of Na+\/I- symporter distribution in human extra-thyroidal tissues","volume":"141","author":"Vayre","year":"1999","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.006_bib22","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1210\/endo.139.10.6329","article-title":"An immunohistochemical study of Na+\/I- symporter in human thyroid tissues and salivary gland tissues","volume":"139","author":"Jhiang","year":"1998","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.006_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10875-010-9507-1","article-title":"Leptin activates human B cells to secrete TNF-\u03b1, IL-6, and IL-10 via JAK2\/STAT3 and p38MAPK\/ERK1\/2 signaling pathway","volume":"31","author":"Agrawal","year":"2011","journal-title":"J\u00a0Clin Immunol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.006_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ando.2013.05.007","article-title":"False-positive iodine-131 whole-body scan findings in patients with differentiated thyroid carcinoma: report of 11 cases and review of the literature","volume":"74","author":"Buton","year":"2013","journal-title":"Ann Endocrinol (Paris)"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:01Z","timestamp":1761516841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22005948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1530891X22005948"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.08.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Associated With Radioactive Iodine Therapy\u2013Acquired Nasolacrimal Duct Obstruction","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}